Effects of Hemodialysis Plus Hemoperfusion in Maintenance Hemodialysis Patients: A Clinical Study

Other illness

• Known allergic reaction, contraindication or intolerance to the material of the dialyzer or perfusion apparatus
• Active bleeding or chronic gastrointestinal bleeding, or other severe bleeding tendencies or coagulation disorders
• History of unstable angina pectoris, myocardial infarction, severe arrhythmia, pericarditis, myocarditis, cardiac surgery or peripheral vascular surgery in the last 8 weeks
• Cerebral hemorrhage in the last 12 weeks
• Severe heart failure (New York Heart Association class IV)
• Acute infection, acute or critical illnesses such as severe cardiac, pulmonary, hepatic or neurological disease and malignancy

Lab values

• Test indicators meeting one or more of the following: white blood cell \<4 x 10\^9/L, platelet count \<60 x 10\^9/L, serum albumin \<30 g/L

Other

• Blood flow \<200 ml/min
• Regular hemoperfusion treatment for more than 3 months and at least once every 2 weeks
• Pregnancy or breastfeeding
• Participation in a clinical trial or ongoing clinical trial within 3 months
• Expected survival of less than 1 year
• Not considered suitable for participation in this trial by the investigator

• Age 18-80 years, regardless of gender
• Stable maintenance hemodialysis for ≥ 3 months with relatively fixed dialysis pattern
• Hemodialysis treatment 3 times per week, total treatment duration ≥ 10 hours per week, vascular access unlimited
• Blood β2-MG \> 30 mg/L and/or 300 pg/ml \< immunoreactive parathyroid hormone (iPTH) \< 800 pg/ml and/or CRP ≥ 16.2 pg/ml
• Kt/V ≥ 1.2 eight weeks prior to enrollment
• Signed informed consent form